<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100907">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012959</url>
  </required_header>
  <id_info>
    <org_study_id>156-08-276</org_study_id>
    <secondary_id>2013-002005-59</secondary_id>
    <nct_id>NCT02012959</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia</brief_title>
  <official_title>A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA ® (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>European Union: European Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to demonstrate that tolvaptan effectively and safely increases
      and maintains serum sodium concentrations in children and adolescent subjects with euvolemic
      or hypervolemic hypernatremia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in serum sodium concentration.</measure>
    <time_frame>Day 2/3, Day 4/5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in serum sodium concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum sodium concentration.</measure>
    <time_frame>Day 2/3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in serum sodium concentration at the end of Day 2/3 from baseline in Phase A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overly rapid increase in serum sodium.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of subjects with overly rapid increase in serum sodium (≥12 mmol/L in 24 hours after 1st dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects requiring rescue medication.</measure>
    <time_frame>Days 4/5</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percentage of subjects requiring rescue medication during Phase A and Phase B of the trial.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum sodium from 24 hours post-last dose to 14 days post-randomization.</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in serum sodium from 24 hours post-last dose to 14 days post-randomization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs of Potential Clinical Relevance - Mean Change from Baseline to study completion.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital Signs of Potential Clinical Relevance - Mean Change from Baseline to study completion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tolvaptan plasma concentration.</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tolvaptan maximum (peak) plasma concentration, time to max (peak) plasma concentration, and area under the concentration-time curve from time zero to 24 hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Body Weight of Potential Clinical Relevance - Mean Change from Baseline to study completion.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Body Weight of Potential Clinical Relevance - Mean Change from Baseline to study completion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Pressure of Potential Clinical Relevance - Mean Change from Baseline to study completion.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood Pressure of Potential Clinical Relevance - Mean Change from Baseline to study completion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Laboratory Tests of Potential Clinical Relevance - Mean Change from Baseline to study completion.</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical Laboratory Tests of Potential Clinical Relevance - Mean Change from Baseline to study completion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluid intake.</measure>
    <time_frame>Day 1/2</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Fluid intake every 6 hours on Days 1 and 2 (Phase A).</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine output.</measure>
    <time_frame>Day 1/2</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Urine output every 6 hours on Days 1 and 2 (Phase A).</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluid balance.</measure>
    <time_frame>Day 1/2</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Fluid balance (intake - output) every 6 hours on Days 1 and 2 (Phase A).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>Tolvaptan Early Withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tolvaptan Late Withdrawal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <arm_group_label>Tolvaptan Early Withdrawal</arm_group_label>
    <arm_group_label>Tolvaptan Late Withdrawal</arm_group_label>
    <other_name>SAMSCA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Male and female subjects ≥ 4 weeks (or ≥44 weeks adjusted gestational age for
             premature births) to &lt;18 years old

          -  Subjects hospitalized with euvolemic or hypervolemic hyponatremia resistant to
             initial standard background therapy

          -  Persistent euvolemic or hypervolemic hyponatremia

          -  Ability to maintain adequate fluid intake (orally or IV)

        Exclusion:

          -  Evidence of hypovolemia or intravascular volume depletion

          -  Serum sodium &lt; 120 mmol/L

          -  Use of potent CYP3A4 inhibitors in subjects ≤ 50 kg or moderate CYP3A4 inhibitors in
             subjects &lt; 20 kg

          -  Lacks free access to water or without ICU-level fluid monitoring and management

          -  History or current diagnosis of nephrotic syndrome

          -  Transient hyponatremia likely to resolve

          -  Hyperkalemia

          -  eGFR &lt; 30 mL/min/1.73 m²

          -  Acute kidney injury

          -  Severe or acute neurological symptoms requiring other intervention

          -  Prior treatment for hyponatremia with hypertonic saline within 8 hours of qualifying
             serum sodium assessments; Urea, lithium, demeclocycline, conivaptan, or tolvaptan
             within 4 days of qualifying serum sodium assessments

          -  Anuria or urinary outflow obstruction

          -  History of hypersensitivity and/or idiosyncratic reaction to benzazepine derivatives

          -  Psychogenic polydipsia

          -  Uncontrolled diabetes mellitus

          -  Screening liver function values &gt; 3 x ULN

          -  Deficient coagulation

          -  Hyponatremia due to the result of any medication that can safely be withdrawn or that
             is most appropriately corrected by alternative therapies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Dandurand, MD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeanette George</last_name>
    <phone>919-926-5965</phone>
    <email>Jeanette.george@incresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simona Ripamonti</last_name>
    <phone>39 02 96199248</phone>
    <email>Simona.Ripamonti@incresearch.com</email>
  </overall_contact_backup>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyponatremia</keyword>
  <keyword>Euvolemic</keyword>
  <keyword>Hypervolemic</keyword>
  <keyword>Serum sodium</keyword>
  <keyword>Dilutional hyponatremia</keyword>
  <keyword>Electrolyte abnormality</keyword>
  <keyword>Electrolyte imbalance</keyword>
  <keyword>Metabolic disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
